Vertex Pharmaceuticals Inc (VRTX)

NASDAQ
Currency in USD
512.23
-1.53(-0.30%)
Closed
Pre Market
512.27+0.04(+0.01%)
VRTX Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
508.52516.50
52 wk Range
377.85519.88
Key Statistics
Edit
Prev. Close
512.23
Open
513.08
Day's Range
508.52-516.5
52 wk Range
377.85-519.88
Volume
1.34M
Average Volume (3m)
1.67M
1-Year Change
24.52%
Book Value / Share
63.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRTX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
496.78
Downside
-3.02%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Vertex Pharmaceuticals Inc Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Inc SWOT Analysis


CF Market Dominance
Explore Vertex's stronghold in cystic fibrosis treatments, with an expanded treatable patient population of 94,000 across multiple regions
Diversification Drive
Delve into Vertex's strategic expansion beyond CF, including FDA approval for Journavx in pain management and the launch of gene therapy CASGEVY
Financial Resilience
Learn about Vertex's robust financial performance, with revenue growth of 10.06% and increased guidance for total product revenues to $10.8-$10.9 billion
Analyst Perspectives
Discover varied analyst views on Vertex, with price targets ranging from $408 to $566, reflecting diverse opinions on the company's growth potential
Read full SWOT analysis

Compare VRTX to Peers and Sector

Metrics to compare
VRTX
Peers
Sector
Relationship
P/E Ratio
−245.6x−0.8x−0.5x
PEG Ratio
2.14−0.010.00
Price/Book
8.0x0.9x2.6x
Price / LTM Sales
11.9x3.0x3.0x
Upside (Analyst Target)
0.6%207.0%53.8%
Fair Value Upside
Unlock20.6%9.6%Unlock

Analyst Ratings

20 Buy
12 Hold
2 Sell
Ratings:
34 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 496.78
(-3.02% Downside)

Earnings

Latest Release
Feb 10, 2025
EPS / Forecast
3.98 / 4.02
Revenue / Forecast
2.91B / 2.79B
EPS Revisions
Last 90 days

People Also Watch

115.43
NVDA
-3.43%
213.85
ABBV
-0.29%
391.37
ADBE
-2.00%
192.82
AMZN
-1.49%
164.25
JNJ
+0.87%

FAQ

What Is the Vertex (VRTX) Stock Price Today?

The Vertex stock price today is 512.23

What Stock Exchange Does Vertex Trade On?

Vertex is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Vertex?

The stock symbol for Vertex is "VRTX."

What Is the Vertex Market Cap?

As of today, Vertex market cap is 131.54B.

What is Vertex Earnings Per Share?

The Vertex EPS is -2.08.

What Is the Next Vertex Earnings Date?

Vertex will release its next earnings report on Apr 30, 2025.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.